Proteasome inhibition in the treatment of cancer

Cell Cycle

Volumn 4, Issue 2, 2005, Pages 289-295

  Richardson, Paul G ^a   Mitsiades, Constantine ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Cancer; I B; Multiple myeloma; NF B; Proteasome; PS 341; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPOXOMICIN; GEMCITABINE; IRINOTECAN; LACTACYSTIN; MELPHALAN; MITOXANTRONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER THERAPY; CELL CYCLE; CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 18344394135     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.2.1414     Document Type: Review

References (99)

1. Adams J. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 2003; 29:3-9.
2. Orlowski M, Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 2000; 383:1-16.
3. Hilt W, Wolf DH. Proteasomes: Destruction as a programme. Trends Biochem Sci 1996; 21:96-102.
4. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8:739-58.
5. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87:7071-5.
6. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274:22123-6.
7. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56:4620-4.
8. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268:533-9.
9. Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, Rammensee HG, Schild H. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998; 95:12504-9.
10. Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, Stevanovic S, Wolf DH, Huber R, Rammensee HG, Schild H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 1998; 273:25637-46.
11. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, Goldberg AL. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 2003; 278:35869-77.
12. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
13. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1999; 1:221-6.
14. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386:463-71.
15. Horwich AL, Weber-Ban EU, Finley D. Chaperone rings in protein folding and degradation. Proc Natl Acad Sci USA 1999; 96:11033-40.
16. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 1998; 94:615-23.
17. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8:307-15.
18. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274:1652-9.
19. Murray AW. Recycling the cell cycle: Cyclins revisited. Cell 2004; 116:221-34.
20. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349:132-8.
21. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11:957-72.
22. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10:1979-90.
23. Gumerlock PH, Kawaguchi T, Moisan LP, Lau AH, Mack PC, Lara PN, Gandara DR. Mechanisms of enhanced cytotoxicity from docetaxel-PS-341 combination in nonsmall cell lung carcinoma. Proc Am Soc Clin Oncol 2002; 21:304a.
24. 2-M-phase arrest and apoptosis in human nonsmall cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-54.
25. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78:773-85.
26. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993; 4:219-29.
27. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2:493-506.
28. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20:2687-95.
29. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-9.
30. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-3.
31. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998; 9:267-76.
32. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: A threonine protease. Science 1995; 268:579-82.
33. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996; 35:3899-908.
34. Chowdary DR, Dermody JJ, Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994; 14:1997-2003.
35. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56:2649-54.
36. Ljungman M. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress. Neoplasia 2000; 2:208-25.
37. Chene P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer 2003; 3:102-9.
38. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7.
39. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
40. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
41. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of nonsmall cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95:176-80.
42. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101:1530-4.
43. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10:3839-52.
44. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-6.
45. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-47.
46. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99:14374-9.
47. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22:8386-93.
48. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004; 104:2886-92.
49. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004; 3:279-90.
50. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22.
51. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-6.
52. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9:1136-44.
53. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelenat H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77:1103-7.
54. Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000; 96:269-74.
55. Chen C, Lin H, Karanes C, Pettit GR, Chen BD. Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis. Cancer Res 2000; 60:4377-85.
56. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5:1062-75.
57. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58:4342-8.
58. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
59. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004.
60. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18:1357-63.
61. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171:88-95.
62. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 nonsmall-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54:343-53.
63. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 nonsmall cell lung cancer cells. J Biol Chem 2003; 278:33714-23.
64. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-22.
65. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100:11-7.
66. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 downregulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004; 95:271-5.
67. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2:835-43.
68. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-28.
69. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl BC, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28.
70. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003; 101:2377-80.
71. Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin Jr AS. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-40.
72. Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P, Cusack Jr JC. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50:183-93.
73. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420-7.
74. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
75. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72.
76. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-23.
77. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory myeloma: An update of the SUMMIT trial with additional follow-up. Hematol J 2004; 5:S103-4.
78. Jagannath S, Richardson P, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine DL, Anderson KC. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): Assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol 2003; 22:582.
79. Mazumder A, Chauvin E, Curran K, Disperati P, Jagannath S. Clinical synergism of bortezomib and chemotherapy in relapsed and refractory multiple myeloma. Blood 2003; 102:390b.
80. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Hematol J 2004; 5:S131.
81. Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B, Shaughnessy JD, Anaissie EJ, Thertulien R, Fassas A, et al. VTD regimen comprising Velcade (V) + thalidomide (T) and added DEX (D) for nonresponders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003; 102:236a.
82. Berenson J, Yang H, Swift R, Sadler K, Vescio R, Adams J, Schenkein D. Bortezomib and melphalan combination therapy in relapsed or refractory multiple myeloma (MM): A phase I/II study. Hematol J 2004; 5(suppl 2):S130.
83. Goy A, Younes P, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, et al. Update on a phase II study of bortezomib in patients with relapsed or refractory indolent or aggressive nonHodgkin's lymphomas. J Clin Oncol 2004; 22(suppl 14S):577S.
84. O'Connor OA, Wright J, Moskowitz CH, MacGregor-Cortelli B, Muzzy J, Straus D, Trehu E, Schenkein DP, Zelenetz AD. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular an mantle cell lymphoma. J Clin Oncol 2004; 22(suppl 14S):578S.
85. Assouline S, Belch A, Sehn L, Kouroukis T, Gascoyne R, Meyer R, Powers J, Eisenhauer E. A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 2003; 102:902a.
86. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10:3371-6.
87. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-11.
88. Fanucchi MP, Belt RJ, Fossella FV, Natale RB, Robert F, Fidias P, Kelly K, Kashala O, Schenkein KP, Schiller JH. Phase (ph) 2 study of bortezomib ± docetaxel inpreviously treated patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Preliminary results. J Clin Oncol 2004; 22(suppl 14S):643s.
89. Albanell J, Baselga J, Guix M, Piccart CJ. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22:16.
90. Lebowitz PF, Harkins C, Conley B, Headlee D, Camphausen K, Guis D, Adams J, Elsayed Y, Sausville E, Van Waes C. Concomitant therapy with proteasome inhibitor, bortezomib, and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 2003; 22:499.
91. Dragovich T, Lenz HJ, Rocha Lima CMS, Kozuch P, Hochster H, O'Neil B, Atiz O, Pipas JM, Kashala O, Schenkein DP. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from a phase (ph) 2b study. J Clin Oncol 2004; 22(suppl 14S):267s.
92. Roth BJ, Dreicer R, Berg W, Myers M, Boral A, Esseltine DL, Oppedisano P, Wang K, Werner M, Schenkein D. Phase I/II trial of bortezomib (PS-341) plus docetaxel in patients with advanced androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2003; 22:228.
93. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-21.
94. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004; 22:115-9.
95. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720-5.
96. Ryan DP, O'Neil B, Lima CR, Eder JP, Lynch TJ, Cusack JC, Supko JG, Dees EC, Esseltine DL, Kashala O. Phase I dose-escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:228.
97. Appleman LJ, Ryan DP, Clark JW, Eder JP, Fishman M, Cusack JC, Fidias P, Supko JG, Esseltine DL, Kashala O. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:581.
98. Dees EC, O'Neil B, Humes E, Hall M, Carey L, Collichio F, Graham M, Esseltine DL, Adams J, Orlowski RZ. Phase I clinical trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22:217.
99. Jagannath S, Durie BGM, Wolf J, Berliner A, Camacho E, Gabayan E, Irwin D, Lutzky J, McKinley M, Potts P, et al. Bortezomib (VELCADE™, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM). Blood 2003; 102:452a.